13th Dec 2021 13:07
(Alliance News) - Midatech Pharma PLC announced on Monday its new investigational drug application has been cleared by the US Food & Drug Administration for phase one study.
Shares in Midatech were up 5.0% at 21.00 pence on Monday in London following the announcement.
The Cardiff-based said the primary objective of the Phase 1 study will be to assess the safety and tolerability of its MTX110 drug in patients with glioblastoma multiforme, a fast-growing tumour of the brain or spinal cord.
The study is expected to include two clinical centres in the US and to begin recruiting the first half of 2022.
MTX110 solubilises panobinostat, an enzyme inhibitor currently used in the treatment of multiple myeloma. In a liquid formulation as MTX110, panobinostat can be delivered directly to a patient's tumour under constant pressure via a catheter system which would then bypass the blood-brain barrier and allow for high drug concentrations and broader drug distribution in and around the tumour. This would also minimise systemic toxicity and other side effects.
Chief Scientific Officer Dmitry Zamoryakhin said this signal finding Phase 1 study could point the way to a new treatment paradigm for this type of cancer.
By Heather Rydings; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
MTPH.L